Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity -; primarily organ transplant recipients who take immunosuppressive medications to reduce the risk of rejection and others with immune system disorders -; do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same age group with normal immune function.
Novel Weekly Oral HIV Drug Safe in Early Trial of Healthy Volunteers
Data from a phase Ia clinical trial of an oral, long-acting integrase inhibitor (GS-1720) in development for HIV demonstrated promising safety in healthy adults without
November 14, 2024